

Marie-Paule Kieny

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5240507/publications.pdf>

Version: 2024-02-01

83
papers

5,916
citations

101496

36
h-index

76872

74
g-index

84
all docs

84
docs citations

84
times ranked

8235
citing authors

#	ARTICLE	IF	CITATIONS
1	One attack on a health worker is one too many. <i>Lancet, The</i> , 2022, 399, e12-e13.	6.3	2
2	Humoral and cellular immune response induced by rVSV ^Î G-ZEBOV-GP vaccine among frontline workers during the 2013â€“2016 West Africa Ebola outbreak in Guinea. <i>Vaccine</i> , 2020, 38, 4877-4884.	1.7	14
3	Lessons learned from Ebola Vaccine R&D during a public health emergency. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2114-2115.	1.4	16
4	Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 738-748.	4.6	62
5	Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model. <i>PLoS ONE</i> , 2018, 13, e0208028.	1.1	18
6	From vaccines to global health to vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1-3.	1.4	0
7	Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability. <i>Vaccine</i> , 2018, 36, 3993-3997.	1.7	15
8	Seasonal vaccines â€“ Critical path to pandemic influenza response. <i>Vaccine</i> , 2017, 35, 851-852.	1.7	18
9	Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. <i>EBioMedicine</i> , 2017, 19, 107-118.	2.7	64
10	Medication Without Harm: WHO's Third Global Patient Safety Challenge. <i>Lancet, The</i> , 2017, 389, 1680-1681.	6.3	279
11	Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases, The</i> , 2017, 17, 833-842.	4.6	27
12	Next Generation Inactivated Poliovirus Vaccine: The Future Has Arrived. <i>Clinical Infectious Diseases</i> , 2017, 64, 1326-1327.	2.9	9
13	Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Æa Suffit!). <i>Lancet, The</i> , 2017, 389, 505-518.	6.3	837
14	Advancing the Right to Healthâ€“The Vital Role of Law. <i>American Journal of Public Health</i> , 2017, 107, 1755-1756.	1.5	33
15	Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. <i>Cell Reports</i> , 2017, 20, 2251-2261.	2.9	107
16	Safety and immunogenicity of rVSV ^Î G-ZEBOV-GP Ebola vaccine in adults and children in LambarÃ©nÃ©, Gabon: A phase I randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002402.	3.9	57
17	Costâ€“effectiveness thresholds: pros and cons. <i>Bulletin of the World Health Organization</i> , 2016, 94, 925-930.	1.5	518
18	A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation. <i>Nature Medicine</i> , 2016, 22, 701-705.	15.2	49

#	ARTICLE	IF	CITATIONS
19	Use open data to curb Zika virus. <i>Nature</i> , 2016, 533, 469-469.	13.7	3
20	Regulatory policy for research and development of vaccines for public health emergencies. <i>Expert Review of Vaccines</i> , 2016, 15, 1075-1077.	2.0	8
21	H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 303-310.	4.6	35
22	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 31-42.	4.6	187
23	Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. <i>New England Journal of Medicine</i> , 2016, 374, 1647-1660.	13.9	355
24	Developing Global Norms for Sharing Data and Results during Public Health Emergencies. <i>PLoS Medicine</i> , 2016, 13, e1001935.	3.9	122
25	The Evolution of the Meningitis Vaccine Project. <i>Clinical Infectious Diseases</i> , 2015, 61, S396-S403.	2.9	36
26	Tough decisions on essential medicines in 2015. <i>Bulletin of the World Health Organization</i> , 2015, 93, 283-284.	1.5	19
27	Rationale for WHO's New Position Calling for Prompt Reporting and Public Disclosure of Interventional Clinical Trial Results. <i>PLoS Medicine</i> , 2015, 12, e1001819.	3.9	108
28	Informing the establishment of the WHO Global Observatory on Health Research and Development: a call for papers. <i>Health Research Policy and Systems</i> , 2015, 13, 9.	1.1	10
29	Building the Human Vaccines Project: strategic management recommendations and summary report of the 15 th July 2014 business workshop. <i>Expert Review of Vaccines</i> , 2015, 14, 629-636.	2.0	6
30	Honouring the value of people in public health: a different kind of p-value. <i>Bulletin of the World Health Organization</i> , 2015, 93, 661-662.	1.5	10
31	Monitoring Progress towards Universal Health Coverage at Country and Global Levels. <i>PLoS Medicine</i> , 2014, 11, e1001731.	3.9	268
32	Health-system resilience: reflections on the Ebola crisis in western Africa. <i>Bulletin of the World Health Organization</i> , 2014, 92, 850-850.	1.5	154
33	Health policy and systems research: building momentum and community. <i>Bulletin of the World Health Organization</i> , 2014, 92, 851-851.	1.5	5
34	The 2014 Ebola outbreak: ethical use of unregistered interventions. <i>Bulletin of the World Health Organization</i> , 2014, 92, 622-622.	1.5	13
35	Ebola Vaccine "An Urgent International Priority. <i>New England Journal of Medicine</i> , 2014, 371, 2249-2251.	13.9	107
36	The International Ebola Emergency. <i>New England Journal of Medicine</i> , 2014, 371, 1180-1183.	13.9	188

#	ARTICLE	IF	CITATIONS
37	Human resources for universal health coverage: from evidence to policy and action. Bulletin of the World Health Organization, 2013, 91, 798-798A.	1.5	19
38	Putting health policy and systems research on the map. Bulletin of the World Health Organization, 2012, 90, 797-797.	1.5	3
39	Health Systems Global, the new international society for health systems research. Health Policy and Planning, 2012, 27, 535-540.	1.0	3
40	Research agenda for mass gatherings: a call to action. Lancet Infectious Diseases, The, 2012, 12, 231-239.	4.6	63
41	Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infectious Diseases, The, 2012, 12, 837-844.	4.6	115
42	Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. Vaccine, 2011, 29, 6191-6218.	1.7	91
43	Complex systems analysis: towards holistic approaches to health systems planning and policy. Bulletin of the World Health Organization, 2011, 89, 242-242.	1.5	42
44	Report of the fourth meeting on "Influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009. Vaccine, 2010, 28, 3875-3882.	1.7	22
45	Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine, 2010, 28, 6811-6820.	1.7	42
46	A vaccine against malaria: a substantial step forward. Lancet, The, 2009, 373, 1411-1412.	6.3	5
47	WHO supports fair access to influenza A (H1N1) vaccine. Bulletin of the World Health Organization, 2009, 87, 653-654.	1.5	6
48	Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine, 2008, 26, 4434-4445.	1.7	124
49	Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults. PLoS ONE, 2008, 3, e1952.	1.1	63
50	Specific Tumor Cell Targeting by a Recombinant MVA Expressing a Functional Single Chain Antibody on the Surface of Intracellular Mature Virus (IMV) Particles. Viral Immunology, 2007, 20, 664-672.	0.6	4
51	Preparedness for Infectious Threats. American Journal of Public Health, 2007, 97, S15-S22.	1.5	7
52	Assembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World. American Journal of Public Health, 2006, 96, 1554-1559.	1.5	33
53	Influenza pandemic vaccines: how to ensure a low-cost, low-dose option. Nature Reviews Microbiology, 2006, 4, 565-566.	13.6	12
54	A review of vaccine research and development: Tuberculosis. Vaccine, 2005, 23, 5725-5731.	1.7	33

#	ARTICLE	IF	CITATIONS
55	Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies. <i>Cancer Gene Therapy</i> , 2002, 9, 470-477.	2.2	20
56	Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth. <i>Cancer Gene Therapy</i> , 2001, 8, 815-826.	2.2	7
57	Persistence of Pathogenic Challenge Virus in Macaques Protected by Simian Immunodeficiency Virus SIVmac1 ₉ nef. <i>Journal of Virology</i> , 2001, 75, 1507-1515.	1.5	27
58	Mucosal immunity and tolerance: relevance to vaccine development. <i>Immunological Reviews</i> , 1999, 170, 197-222.	2.8	224
59	Production of cholera toxin B subunit in <i>Lactobacillus</i> . <i>FEMS Microbiology Letters</i> , 1998, 169, 29-36.	0.7	42
60	HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. <i>Nature Medicine</i> , 1995, 1, 321-329.	15.2	74
61	A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI). <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 373-381.	0.5	145
62	Safety and Immunogenicity of a Recombinant HIV Type 1 Glycoprotein 160 Boosted by a V3 Synthetic Peptide in HIV-Negative Volunteers. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1479-1486.	0.5	31
63	Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins. <i>Vaccine</i> , 1995, 13, 202-208.	1.7	8
64	Kex2p: a model for cellular endoprotease processing human immunodeficiency virus type 1 envelope glycoprotein precursor. <i>FEBS Journal</i> , 1994, 225, 565-572.	0.2	10
65	Diversity of V3 Region Sequences of Human Immunodeficiency Viruses Type 1 from the Central African Republic. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 997-1006.	0.5	150
66	Vaccinia Virus MUC1 Immunization of Mice. <i>Journal of Immunotherapy</i> , 1993, 14, 136-143.	1.2	68
67	Identification of a Neutralizing Domain in the External Envelope Glycoprotein of Simian Immunodeficiency Virus. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 1165-1170.	0.5	53
68	Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. <i>Aids</i> , 1992, 6, 1249-1258.	1.0	71
69	Detection of gag-Specific Cytotoxic T Lymphocytes in HIV-2ben-Infected Macaques. , 1992, , 103-113.		0
70	Interaction of Human Epidermal Langerhans Cells with HIV-1 Viral Envelope Proteins (gp 120 and gp) Tj ETQq0 0 0 rgBT /Overlock 10 T <i>Dermatology</i> , 1991, 18, 377-392.	0.6	20
71	Antibody Responses of Chimpanzees Immunized with Synthetic Peptides Corresponding to Full-Length V3 Hypervariable Loops of HIV-1 Envelope Glycoproteins. <i>AIDS Research and Human Retroviruses</i> , 1991, 7, 813-823.	0.5	25
72	An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. <i>Aids</i> , 1990, 4, 841-846.	1.0	39

#	ARTICLE	IF	CITATIONS
73	Immunogenicity and Epitope Mapping of a Recombinant Soluble gp160 of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein. <i>AIDS Research and Human Retroviruses</i> , 1990, 6, 1107-1113.	0.5	23
74	Cell-Mediated Immune Proliferative Responses to HIV-1 of Chimpanzees Vaccinated with Different Vaccinia Recombinant Viruses. <i>AIDS Research and Human Retroviruses</i> , 1989, 5, 41-50.	0.5	32
75	Antibodies to the <i>nef</i> Protein and to <i>nef</i> Peptides in HIV-1 Infected Seronegative Individuals. <i>AIDS Research and Human Retroviruses</i> , 1989, 5, 279-291.	0.5	69
76	USE OF RECOMBINANT VACCINIA-RABIES GLYCOPROTEIN VIRUS FOR ORAL VACCINATION OF WILDLIFE AGAINST RABIES: INNOCUITY TO SEVERAL NON-TARGET BAIT CONSUMING SPECIES. <i>Journal of Wildlife Diseases</i> , 1989, 25, 540-547.	0.3	73
77	Multiple subsets of HIV-specific cytotoxic T lymphocytes in humans and in mice. <i>European Journal of Immunology</i> , 1989, 19, 1537-1544.	1.6	48
78	An antigenic peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B. <i>European Journal of Immunology</i> , 1989, 19, 2383-2386.	1.6	94
79	Isolation of recombinant partial gag gene product p18 (HIV-1Bru) from <i>Escherichia coli</i> . <i>Journal of Chromatography A</i> , 1989, 476, 99-112.	1.8	6
80	Candidate vaccines for HIV. <i>Vaccine</i> , 1989, 7, 188-189.	1.7	3
81	HIV-specific T lymphocyte immunity in mice immunized with a recombinant vaccinia virus. <i>European Journal of Immunology</i> , 1988, 18, 1917-1924.	1.6	23
82	Recombinant polyoma virus-vaccinia viruses: T antigen expression vectors and anti-tumor immunization agents. <i>Biochimie</i> , 1988, 70, 1075-1087.	1.3	6
83	Isotypic Restriction of the Antibody Response to Human Immunodeficiency Virus. <i>AIDS Research and Human Retroviruses</i> , 1988, 4, 3-9.	0.5	78